CAMBRIDGE, England & STEVENAGE, England--(BUSINESS WIRE)--Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), and ...

New data from CGT Catapult has demonstrated progression by the industry toward commercialization of therapies and an increase in GMP manufacturing space. New data from the Cell and Gene Therapy ...

LONDON, October 06, 2025--(BUSINESS WIRE)--Mytos, a biotechnology company automating cell manufacturing, today announced the launch of its automated contract development and manufacturing organization ...

LONDON--(BUSINESS WIRE)--Cell Medica today announced the acquisition of Catapult Therapy TCR Limited, a subsidiary of Cell and Gene Therapy Catapult (CGT Catapult), and the initiation of a ...

LONDON, Sept. 23, 2021 /PRNewswire/ -- Quell Therapeutics Ltd ("Quell"), the world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the ...

TrakCel solution integration with Cell and Gene Therapy Catapult manufacturing centre enables needle-to-needle supply chain management at any scale The Cell and Gene Therapy Catapult (CGT Catapult) ...

TrakCel said today it will incorporate its needle-to-needle supply chain management platform into the Cell and Gene Therapy (CGT) Catapult’s large-scale cell and gene therapy manufacturing center set ...

The Cell and Gene Therapy Catapult and pHion Therapeutics announced an exclusive licence agreement for pHion’s proprietary RALA technology for ex-vivo applications. The agreement builds upon the ...

On March 11, 2021, Cell and Gene Therapy Catapult (CGT Catapult) announced that GlaxoSmithKline (GSK) will expand its clinical trial manufacturing capacity for cell and gene therapies at CGT ...

Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), and the Cell and Gene Therapy Catapult (CGT Catapult), an ...

Collaboration to facilitate an expanded manufacturing footprint to enable clinical supply of Quell's pipeline, including QEL-001 in liver transplantation and pipeline programs in neuroinflammation and ...